Raloxifene (Evista)

Subscribe to Selected New Research on Raloxifene

916 relevant articles (96 outcomes, 278 trials/studies) found for this Drug

Description: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Also Known As:

Evista; ELi Lilly Brand of Raloxifene; Keoxifene; Keoxifene Hydrochloride; LY 139481; LY 156758; LY-139481; LY-156758; Lilly Brand of Raloxifene; Raloxifene Hydrochloride; LY139481; LY156758; Raloxifene Lilly Brand; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Benzylidene Compounds

Experts

1.	Jordan, V Craig: 7 articles (06/2008 - 02/2002)
2.	Palomba, Stefano: 7 articles (07/2005 - 08/2002)
3.	Zullo, Fulvio: 7 articles (07/2005 - 08/2002)
4.	Cauley, Jane A: 6 articles (06/2008 - 01/2002)
5.	Cummings, Steven R: 6 articles (09/2006 - 01/2002)
6.	Lombardi, Gaetano: 6 articles (07/2005 - 08/2002)
7.	Orio, Francesco: 6 articles (07/2005 - 08/2002)
8.	Russo, Tiziana: 6 articles (07/2005 - 08/2002)
9.	Barrett-Connor, Elizabeth: 5 articles (06/2008 - 03/2003)
10.	Sarkar, Somnath: 5 articles (04/2005 - 05/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2004 - "Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction." 01/01/2004 - "It seems clear that raloxifene increases bone mineral density, has no effect on the endometrium, and holds high promise for the prevention of breast cancer" 06/15/2001 - "The women with the highest BMD and those with a family history of breast cancer experienced a significantly greater therapy benefit with raloxifene, compared with the two thirds of patients with lower BMD or those without a family history, respectively; the subgroup-by-therapy interactions were significant (P =.005 and P =.015, respectively)" 12/01/2003 - "Raloxifene therapy was also associated with a favorable or neutral effect in the cardiovascular system, and a reduced incidence of breast cancer" 05/01/2008 - "RESULTS/CONCLUSIONS: Different placebo-controlled trials indicated that raloxifene is effective in reducing invasive breast cancer risk in postmenopausal women" Order ALL the reference details at left...
2.	Osteoporosis 07/01/2007 - "CONCLUSIONS: In postmenopausal women with osteoporosis, low-dose HRT produced significantly greater increases in BMD of the lumbar spine and total body and greater decreases in bone turnover than raloxifene at 12 months." 02/01/2006 - "The definite anti-fracture efficacy of raloxifene at the spine, its plausible effect on non-spine fracture in high-risk patients and its beneficial effect on breast and heart make this compound an interesting approach for women presenting with osteoporosis" 01/01/2006 - "In conclusion, raloxifene treatment at 60 mg/day for 1 year resulted in a significant reduction in the risk of new clinical vertebral fractures and any new clinical fracture in postmenopausal Asian women with osteoporosis." 08/01/2000 - "In randomised placebo-controlled studies involving postmenopausal women or patients with osteoporosis, raloxifene 60 to 150 mg/day was effective in increasing bone mineral density (BMD) over 12- to 36-month periods" 01/01/2004 - "Raloxifene, a selective oestrogen receptor modulator, is effective in the treatment of osteoporosis without stimulating the breast and the endometrium" Order ALL the reference details at left...
3.	Postmenopausal Osteoporosis 01/01/2000 - "Raloxifene is effective in preventing bone loss and may prevent fractures in postmenopausal osteoporosis" 01/01/2008 - "has completed a phase III trial comparing bazedoxifene with raloxifene and placebo in 7492 patients with moderate-to-severe postmenopausal osteoporosis" 08/01/2007 - "The outcome of the Raloxifene Use for the Heart (RUTH) trial will determine whether raloxifene, currently approved for the treatment of post-menopausal osteoporosis, could substitute for HRT in alleviating cardiovascular symptoms in post-menopausal women." 09/01/2006 - "The purpose of this study was to determine if raloxifene at therapeutic doses affects platelet function in patients with postmenopausal osteoporosis" 11/01/1998 - "Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial." Order ALL the reference details at left...
4.	Neoplasms (Cancer) 07/01/2003 - "RESULTS: The patients had a significant response to raloxifene therapy, with complete remission in 8 cases and partial response in 5 cases, evaluated by regression of symptoms and tumor size" 04/23/2008 - "Previous studies have demonstrated that raloxifene induces apoptosis in a variety of cancer cell lines" 01/01/1999 - "Clinical studies on postmenopausal osteoporotic women on raloxifene as compared with placebo show a significant decrease in the rate of newly diagnosed breast cancers" 10/01/1995 - "Further studies are needed to define the maximal antitumor efficacy and the mechanism of action of raloxifene in urogenital solid tumor animal models" 09/01/2008 - "Endometrial tumors in raloxifene users had a more favorable histologic profile and were predominantly International Federation of Gynecology and Obstetrics stage I and low grade" Order ALL the reference details at left...
5.	Metabolic Bone Diseases (Osteopenia) 05/01/2003 - "STUDY DESIGN: Postmenopausal women with osteopenia who were otherwise healthy were assigned randomly in a double blind-fashion to receive placebo (n = 16 women) or raloxifene (60 mg/d, n = 16 women)" 05/01/2003 - "Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study." 01/01/2007 - "CONCLUSION: For 55 and 60 year old women with osteopenia, treatment with raloxifene compares favorably to interventions accepted as cost-effective." 09/01/2003 - "For clinically apparent vertebral fractures, the relative risk of fracture in the osteopenia group for raloxifene was 0.25 (0.04-0.63) compared with placebo" 09/01/2002 - "CONCLUSIONS: High-dose raloxifene prevented the development of osteopenia in the ovariectomized monkey by reducing bone turnover, albeit to a lesser extent than CEE" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Selective Estrogen Receptor Modulators (SERM)
3.	Estrogens (Estrogen)
4.	Alendronate (Alendronate Sodium)
5.	Estradiol (Estrace)
6.	Raloxifene (Evista)
7.	risedronic acid (risedronate)
8.	Calcitonin (Calcitonin, Eel)
9.	Diphosphonates
10.	Aromatase Inhibitors

Related Therapies and Procedures

1.	Chemoprevention
2.	Hysterectomy
3.	Estrogen Replacement Therapy
4.	Drug Therapy (Chemotherapy)
5.	Female Contraceptive Devices (Vaginal Ring)

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3579 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>